Last updated on November 2019

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal Paediatric Subjects With Asthma Over a Year


Brief description of study

There is a regulatory requirement to evaluate the extent of reduction (if any) of growth velocity associated with inhaled corticosteroid (ICS) containing products that are to be administered to children, and to this end there is Food and Drug Administration (FDA) regulatory guidance. This is a randomised, single-blind (run-in period)/double-blind (treatment period), parallel group, placebo controlled, multicentre study to assess the effect of once daily (OD) inhaled fluticasone furoate (FF) 50 microgram (mcg) on growth velocity in prepubertal asthmatic children on a background therapy of open-label montelukast. This study will be conducted over a total duration of approximately 76 weeks: 16-week run-in period (single-blind placebo inhaler), 52-week double-blind treatment period (inhaled FF 50 mcg /placebo administered OD in the morning for 52 weeks) and 8-week follow-up period. The purpose of the study is to evaluate the magnitude of effect (with a level of precision) on growth velocity of prepubertal asthmatic paediatric subjects (aged 5 to <9 years) following administration of OD inhaled FF 50 mcg for one year. This study fulfills European Union (EU) and United States (US) regulatory requirements for the evaluation of potential growth suppression in children.

Clinical Study Identifier: NCT02889809

Find a site near you

Start Over

GSK Investigational Site

Little Rock, AR United States
  Connect »

GSK Investigational Site

Huntington Beach, CA United States
  Connect »

GSK Investigational Site

Homestead, FL United States
  Connect »

GSK Investigational Site

Loxahatchee Groves, FL United States
  Connect »

GSK Investigational Site

Miami, FL United States
  Connect »

GSK Investigational Site

Saint Petersburg, FL United States
  Connect »

GSK Investigational Site

Gainesville, GA United States
  Connect »

GSK Investigational Site

Ypsilanti, MI United States
  Connect »

GSK Investigational Site

Bellevue, NE United States
  Connect »

GSK Investigational Site

Raleigh, NC United States
  Connect »

GSK Investigational Site

Oklahoma City, OK United States
  Connect »

GSK Investigational Site

Medford, OR United States
  Connect »

GSK Investigational Site

Pittsburgh, PA United States
  Connect »

GSK Investigational Site

Orangeburg, SC United States
  Connect »

GSK Investigational Site

Live Oak, TX United States
  Connect »

GSK Investigational Site

San Antonio, TX United States
  Connect »

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Capital Federal, Argentina
  Connect »

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Gdansk-Wrzeszcz, Poland
  Connect »

GSK Investigational Site

Skarzysko-Kamienna, Poland
  Connect »

GSK Investigational Site

Sangiorgiu De Mures, Romania
  Connect »

GSK Investigational Site

Moscow, Russian Federation
  Connect »

GSK Investigational Site

Novosibirsk, Russian Federation
  Connect »

GSK Investigational Site

Saint Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Saint-Petersburg, Russian Federation
  Connect »

GSK Investigational Site

St.Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Tomsk, Russian Federation
  Connect »

GSK Investigational Site

Voronezh, Russian Federation
  Connect »

GSK Investigational Site

Yaroslavl, Russian Federation
  Connect »

GSK Investigational Site

Middelburg, South Africa
  Connect »

GSK Investigational Site

Bellville, South Africa
  Connect »

GSK Investigational Site

Cape Town, South Africa
  Connect »

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »